How Ebola Infection Begins: The First 72 Hours Inside the Human Body

The Invisible Invasion

Most people who survive Ebola never know exactly when infection began. The virus leaves no immediate trace — no pain at the site of entry, no instant fever, no warning signal. For the first two to four days after exposure, the infected person feels entirely normal while the virus conducts a systematic takeover of the immune system’s first responders.

Understanding what happens in those early hours matters enormously. It explains why Ebola is so difficult to detect before symptoms appear, why the window for effective treatment is narrow, and why experimental antivirals must be given early to have any impact.

Hour 0–6: Viral Entry

Ebola virus enters the body through mucous membranes (eyes, nose, mouth), broken skin, or direct contact with infected bodily fluids. Unlike respiratory viruses, it cannot be inhaled as an aerosol under natural conditions — a key fact that limits its transmission compared to influenza or SARS-CoV-2, but does not make it any less lethal once established.

The virus’s glycoprotein (GP) — the spike-like protein covering its surface — binds to receptors on the surface of host cells. Unlike many viruses that have highly specific receptor targets, Ebola GP can bind to several receptor types, including:

NPC1 (Niemann-Pick C1): the primary intracellular receptor, found in the endosomal membrane
TIM-1: expressed on mucous membranes, facilitating initial entry
Integrins and lectins: on macrophages and dendritic cells — the immune system’s first-line scouts

This broad receptor range is the first sign of Ebola’s evolutionary sophistication: it specifically targets the cells that are supposed to detect and destroy it.

Hour 6–24: Conquering the Immune Scouts

The virus’s primary initial targets are macrophages and dendritic cells — the sentinels of the innate immune system. These cells patrol tissues, engulf pathogens, and send alarm signals to activate the broader immune response.

In a normal infection (say, influenza), macrophages engulf the virus, detect it as foreign, and release interferons — chemical signals that put surrounding cells on high alert, slowing viral replication and alerting T-cells and NK cells. This is why most viral infections produce rapid fever and malaise: the immune system is doing its job.

Ebola has evolved to specifically disable this alarm system. Two viral proteins — VP35 and VP24 — work together to suppress interferon production and block interferon signalling in infected cells:

VP35 binds to double-stranded RNA (the molecular pattern that signals “virus present”) and masks it from the cellular sensors (RIG-I, MDA5) that would trigger interferon production
VP24 blocks the transport of activated interferon-signalling molecules into the cell nucleus, preventing the interferon response from being “read”

The result: macrophages and dendritic cells are infected, begin replicating virus, but do not trigger the alarm. The virus has hijacked the immune system’s scouts and turned them into silent factories.

Hour 24–48: Spreading Through the Lymphatic Highway

By the second day, infected macrophages — now carrying millions of newly replicated viral particles — begin travelling through the lymphatic system to regional lymph nodes, and from there into the bloodstream.

This is a critical phase. The lymph nodes are where the adaptive immune system is activated — where B-cells and T-cells are primed to recognise specific pathogens. Normally, infected dendritic cells arriving at lymph nodes would present viral fragments to T-cells, triggering a targeted immune response.

Instead, Ebola-infected dendritic cells fail to activate T-cells effectively. Research suggests the virus interferes with MHC class II antigen presentation — the molecular “show-and-tell” process by which dendritic cells display pathogen fragments to T-cells. T-cells are not primed. The adaptive immune response is delayed by days.

Meanwhile, the virus is entering the bloodstream and reaching the liver, adrenal glands, and spleen — organs rich in macrophages and highly vascularised. Infection is now systemic.

Hour 48–72: The Cytokine Paradox

By 72 hours post-infection, a paradox begins to emerge that defines Ebola’s lethality.

Although the virus has successfully suppressed the early, targeted interferon response, the sheer scale of cellular infection begins triggering a massive, non-specific inflammatory response — a cytokine storm. Infected macrophages, now overwhelmed and dying, release enormous quantities of pro-inflammatory cytokines:

TNF-α (tumour necrosis factor)
IL-6 and IL-8 (interleukins)
MCP-1 (monocyte chemoattractant protein)

These signals are the immune system’s emergency override — a blunt-instrument response when the precision response has been disabled. The cytokine flood produces the first clinical symptoms: fever, severe headache, fatigue, muscle pain. These appear, on average, 4–10 days after exposure (the incubation period), but the biochemical process driving them has been underway since day one.

The cytokine storm also begins attacking the endothelial cells lining blood vessels. Ebola’s GP protein directly damages endothelial cells; the inflammatory cytokines compound this damage. Vascular integrity begins to deteriorate — the biological basis for the haemorrhagic symptoms that define later-stage disease.

Why Early Treatment Matters So Much

The 72-hour window has direct clinical implications. Two approved treatments for Zaire ebolavirus — Inmazeb (atoltivimab/maftivimab/odesivimab) and Ebanga (ansuvimab) — are monoclonal antibodies that neutralise viral GP, preventing further cellular entry.

Animal model data and the clinical trials that led to their approval both show the same pattern: treatment efficacy falls sharply with each day of delay. In the PALM trial (2019), survival rates with Inmazeb were:

89% when administered within the first 3 days of symptoms
67% when administered days 4–7
Below 50% after day 7

The reason is precisely what the first 72 hours describe: by the time symptoms are severe, viral dissemination is already systemic, cytokine damage to the vasculature is underway, and the window for neutralising GP before irreversible organ damage occurs is closing.

What Survivors’ Immune Responses Look Like

Not everyone who is infected progresses to severe disease. Studies of survivors from the 2014–2016 West Africa epidemic found that survivors showed one key immunological difference: they mounted an early, robust innate immune response before the adaptive response kicked in.

Specifically, survivors showed:

Higher early natural killer (NK) cell activity
Faster production of IgM antibodies (within the first week)
Less pronounced cytokine storms (lower TNF-α and IL-6 peaks)
Better preservation of T-cell function

This suggests that individuals with certain innate immune characteristics — possibly genetic, possibly related to prior exposure to cross-reactive pathogens — can partially resist Ebola’s immune evasion strategy and buy enough time for the adaptive immune response to develop. It also provides a roadmap for what therapeutic interventions should aim to achieve.

The Implications for Bundibugyo and Sudan Strains

The molecular mechanisms described above apply primarily to Zaire ebolavirus, the best-studied species. However, all Ebola species share the same fundamental architecture: the same VP35 and VP24 interferon-blocking mechanism, the same macrophage and dendritic cell tropism, the same endothelial targeting.

This is why the lack of approved treatments for Bundibugyo and Sudan strains is so clinically significant. Even though a Bundibugyo patient’s first 72 hours may look almost identical at the cellular level to a Zaire case, there is no approved monoclonal antibody to interrupt that process. Response is limited to supportive care — managing the consequences of the cytokine storm and vascular damage rather than stopping the underlying viral replication.

Sources: Feldmann & Geisbert (2011) Nature Reviews Microbiology; WHO Ebola Clinical Management Guidelines (2022); PALM trial data (New England Journal of Medicine, 2019); Ebola survivor immune profiling, Lancet Infectious Diseases (2016).